Healthcare / BiotechnologyCopenhagen
$570.00
-25.00 (-4.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-3.4M · quality 56.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$24M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-4.7%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-691.3%
FCF / Net income
2.49x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $309000.0 · net income $-859000.0 · FCF $-2.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $309000.00 | $309000.00 | — | — | — |
| Net Income | $-859000.00 | $-859000.00 | $-298000.00 | $-26.0M | $-626.5M |
| EBITDA | $-2.4M | $-2.4M | $-201000.00 | $-12.9M | $-65.3M |
| EPS | -21.00 | -21.00 | -8.00 | -738.00 | -17940.00 |
| Operating Margin | -791.6% | -791.6% | — | — | — |
| Net Margin | -278.0% | -278.0% | — | — | — |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | — | 4.28 |
| Current Ratio | 13.90 | 13.90 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.1M | $-2.1M | $-3.4M | $-20.0M | $-603.6M |
| Returns | |||||
| ROE | -4.7% | -4.7% | -1.5% | -182.9% | -6708.8% |
| Valuation | |||||
| P/B | 1.29 | 1.29 | 1.58 | 3.24 | 60.21 |
| Growth & Yield | |||||
| EPS Growth | -162.5% | -162.5% | 98.9% | 95.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-47.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-8.00 → -21.00
Residual
-47.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.